Skip to main content
Top
Published in: Thrombosis Journal 1/2017

Open Access 01-12-2017 | Research

Pro-coagulant activity during exercise testing in patients with coronary artery disease

Authors: Joanna Cwikiel, Ingebjorg Seljeflot, Eivind Berge, Harald Arnesen, Kristian Wachtell, Hilde Ulsaker, Arnljot Flaa

Published in: Thrombosis Journal | Issue 1/2017

Login to get access

Abstract

Background

Strenuous exercise may trigger myocardial infarction through increased pro-coagulant activity. We aimed to investigate whether patients referred for exercise testing, who were found to have angiographically verified coronary artery disease (CAD), have a more hypercoagulable profile during exercise testing than those without CAD.

Methods

Patients with symptoms of stable CAD were examined with exercise electrocardiography on bicycle ergometer. Venous blood samples were taken at rest and within 5 min after end of exercise. The following haemostatic variables were analyzed: tissue factor pathway inhibitor (TFPI) activity and antigen, prothrombin fragment 1 + 2 (F1 + 2), D-dimer and endogenous thrombin potential (ETP). All participants underwent conventional coronary angiography. CAD was defined as having any degree of atherosclerosis.

Results

Out of the 106 patients enrolled, 70 were found to have CAD. Mean exercise duration was 10:06 ± 4:11 min, with no significant differences between the groups. A significant increase from baseline to after exercise testing was observed in all measured markers in the total population (p ≤ 0.002 for all). In patients with angiographically verified CAD, total TFPI was significantly lower at baseline compared to patients without CAD (median value 67.4 and 76.6 ng/ml respectively, p = 0.027). However, no significant differences in changes of any of the measured markers during exercise were observed between the two groups.

Conclusion

Pro-coagulant activity increased during short-term strenuous exercise testing in patients with symptoms suggestive of CAD. However the hypercoagulable state observed, was not more pronounced in patients with angiographically verified CAD compared to patients without CAD. NCT01495091.
Literature
1.
go back to reference Ross R. Atherosclerosis - inflammatory disease. NEJM. 1999;340 Ross R. Atherosclerosis - inflammatory disease. NEJM. 1999;340
3.
go back to reference Okafor ON, Gorog DA. Endogenous Fibrinolysis: An Important Mediator of Thrombus Formation and Cardiovascular Risk. J Am Coll Cardiol. 2015;65:1683–99.CrossRefPubMed Okafor ON, Gorog DA. Endogenous Fibrinolysis: An Important Mediator of Thrombus Formation and Cardiovascular Risk. J Am Coll Cardiol. 2015;65:1683–99.CrossRefPubMed
4.
go back to reference Ardissino D, Merlini PA, Ariëns R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997;349:769–71.CrossRefPubMed Ardissino D, Merlini PA, Ariëns R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997;349:769–71.CrossRefPubMed
5.
go back to reference Rendu F, Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets. 2001;12:261–73.CrossRefPubMed Rendu F, Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets. 2001;12:261–73.CrossRefPubMed
6.
go back to reference Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553–61.PubMed Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553–61.PubMed
7.
go back to reference Posthuma JJ, van der Meijden PE, Ten Cate H, Spronk HM. Short- and Long-term exercise induced alterations in haemostasis: a review of the literature. Blood Rev. 2015;29:171–8.CrossRefPubMed Posthuma JJ, van der Meijden PE, Ten Cate H, Spronk HM. Short- and Long-term exercise induced alterations in haemostasis: a review of the literature. Blood Rev. 2015;29:171–8.CrossRefPubMed
8.
go back to reference Womack CJ, Nagelkirk PR, Coughlin AM. Exercise-induced changes in coagulation and fibrinolysis in healthy populations and patients with cardiovascular disease. Sports Med. 2003;33:795–807.CrossRefPubMed Womack CJ, Nagelkirk PR, Coughlin AM. Exercise-induced changes in coagulation and fibrinolysis in healthy populations and patients with cardiovascular disease. Sports Med. 2003;33:795–807.CrossRefPubMed
9.
go back to reference Acil T, Atalar E, Sahiner L, Kaya B, Haznedaroglu IC, Tokgozoglu L, Ovunc K, Aytemir K, Ozer N, Oto A, Ozmen F, Nazli N, Kes S, Aksoyek S. Effects of acute exercise on fibrinolysis and coagulation in patients with coronary artery disease. Int Heart J. 2007;48:277–85.CrossRefPubMed Acil T, Atalar E, Sahiner L, Kaya B, Haznedaroglu IC, Tokgozoglu L, Ovunc K, Aytemir K, Ozer N, Oto A, Ozmen F, Nazli N, Kes S, Aksoyek S. Effects of acute exercise on fibrinolysis and coagulation in patients with coronary artery disease. Int Heart J. 2007;48:277–85.CrossRefPubMed
11.
go back to reference Weiss C, Velich T, Niebauer J, Hauer K, Kälberer B, Kübler W, Bärtsch P. Activation of coagulation and fibrinolysis after rehabilitative exercise in patients with coronary artery disease. Am J Cardiol. 1998;81:672–7.CrossRefPubMed Weiss C, Velich T, Niebauer J, Hauer K, Kälberer B, Kübler W, Bärtsch P. Activation of coagulation and fibrinolysis after rehabilitative exercise in patients with coronary artery disease. Am J Cardiol. 1998;81:672–7.CrossRefPubMed
12.
go back to reference Gorog DA. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol. 2010;55:2701–9.CrossRefPubMed Gorog DA. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol. 2010;55:2701–9.CrossRefPubMed
13.
go back to reference Sedaghat-Hamedani F, Kayvanpour E, Frankenstein L, Mereles D, Amr A, Buss S, Keller A, Giannitsis E, Jensen K, Katus HA, Meder B. Biomarker changes after strenuous exercise can mimic pulmonary embolism and cardiac injury--a metaanalysis of 45 studies. Clin Chem. 2015;61:1246–55.CrossRefPubMed Sedaghat-Hamedani F, Kayvanpour E, Frankenstein L, Mereles D, Amr A, Buss S, Keller A, Giannitsis E, Jensen K, Katus HA, Meder B. Biomarker changes after strenuous exercise can mimic pulmonary embolism and cardiac injury--a metaanalysis of 45 studies. Clin Chem. 2015;61:1246–55.CrossRefPubMed
14.
go back to reference Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, Lubos E, Münzel T, Peetz D, Nicaud V, Juhan-Vague I, Tiret L, Atherogene I. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost. 2007;5:475–82.CrossRefPubMed Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, Lubos E, Münzel T, Peetz D, Nicaud V, Juhan-Vague I, Tiret L, Atherogene I. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost. 2007;5:475–82.CrossRefPubMed
15.
go back to reference Golino P, Ravera A, Ragni M, Cirillo P, Piro O, Chiariello M. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation. 2003;108:2864–9.CrossRefPubMed Golino P, Ravera A, Ragni M, Cirillo P, Piro O, Chiariello M. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation. 2003;108:2864–9.CrossRefPubMed
16.
go back to reference Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost. 1998;79:495–9.PubMed Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost. 1998;79:495–9.PubMed
17.
go back to reference Morise AP, Haddad WJ, Beckner D. Development and validation of a clinical score to estimate the probability of coronary artery disease in men and women presenting with suspected coronary disease. Am J Med. 1997;102:350–6.CrossRefPubMed Morise AP, Haddad WJ, Beckner D. Development and validation of a clinical score to estimate the probability of coronary artery disease in men and women presenting with suspected coronary disease. Am J Med. 1997;102:350–6.CrossRefPubMed
18.
go back to reference Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377–81.PubMed Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377–81.PubMed
19.
go back to reference Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, Coke LA, Fleg JL, Forman DE, Gerber TC, Gulati M, Madan K, Rhodes J, Thompson PD, Williams MA, American Heart Association Exercise CR, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128:873–934.CrossRefPubMed Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, Coke LA, Fleg JL, Forman DE, Gerber TC, Gulati M, Madan K, Rhodes J, Thompson PD, Williams MA, American Heart Association Exercise CR, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128:873–934.CrossRefPubMed
20.
go back to reference Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1995;15:2055–62.CrossRefPubMed Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1995;15:2055–62.CrossRefPubMed
21.
go back to reference Kawaguchi A, Miyao Y, Noguchi T, Nonogi H, Yamagishi M, Miyatake K, Kamikubo Y, Kumeda K, Tsushima M, Yamamoto A, Kato H. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. Arterioscler Thromb Vasc Biol. 2000;20:251–8.CrossRefPubMed Kawaguchi A, Miyao Y, Noguchi T, Nonogi H, Yamagishi M, Miyatake K, Kamikubo Y, Kumeda K, Tsushima M, Yamamoto A, Kato H. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. Arterioscler Thromb Vasc Biol. 2000;20:251–8.CrossRefPubMed
22.
go back to reference Saigo M, Abe S, Ogawa M, Yamashita T, Biro S, Minagoe S, Maruyama I, Tei C. Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost. 2001;86:1197–203.PubMed Saigo M, Abe S, Ogawa M, Yamashita T, Biro S, Minagoe S, Maruyama I, Tei C. Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost. 2001;86:1197–203.PubMed
23.
go back to reference Blann AD, Amiral J, McCollum CN, Lip GY. Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls. Atherosclerosis. 2000;152:29–34.CrossRefPubMed Blann AD, Amiral J, McCollum CN, Lip GY. Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls. Atherosclerosis. 2000;152:29–34.CrossRefPubMed
24.
go back to reference Mitchell CT, Kamineni A, Palmas W, Cushman M. Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2009;207:277–83.CrossRefPubMedPubMedCentral Mitchell CT, Kamineni A, Palmas W, Cushman M. Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2009;207:277–83.CrossRefPubMedPubMedCentral
25.
go back to reference Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I, PRIME SG. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation. 2004;109:1343–8.CrossRefPubMed Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I, PRIME SG. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation. 2004;109:1343–8.CrossRefPubMed
26.
go back to reference Empana JP, Canoui-Poitrine F, Luc G, Juhan-Vague I, Morange P, Arveiler D, Ferrieres J, Amouyel P, Bingham A, Montaye M, Ruidavets JB, Haas B, Evans A, Ducimetiere P, PRIME SG. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. Eur Heart J. 2008;29:1966–74.CrossRefPubMed Empana JP, Canoui-Poitrine F, Luc G, Juhan-Vague I, Morange P, Arveiler D, Ferrieres J, Amouyel P, Bingham A, Montaye M, Ruidavets JB, Haas B, Evans A, Ducimetiere P, PRIME SG. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. Eur Heart J. 2008;29:1966–74.CrossRefPubMed
27.
go back to reference Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation. 1999;99:2908–13.CrossRefPubMed Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation. 1999;99:2908–13.CrossRefPubMed
28.
go back to reference Cimenti C, Schlagenhauf A, Leschnik B, Schretter M, Tschakert G, Gröschl W, Seibert FJ, Hofmann P, Muntean WE. Low endogenous thrombin potential in trained subjects. Thromb Res. 2013;131:e281–5.CrossRefPubMed Cimenti C, Schlagenhauf A, Leschnik B, Schretter M, Tschakert G, Gröschl W, Seibert FJ, Hofmann P, Muntean WE. Low endogenous thrombin potential in trained subjects. Thromb Res. 2013;131:e281–5.CrossRefPubMed
29.
go back to reference Hilberg T, Prasa D, Stürzebecher J, Gläser D, Gabriel HH. Thrombin potential and thrombin generation after exhaustive exercise. Int J Sports Med. 2002;23:500–4.CrossRefPubMed Hilberg T, Prasa D, Stürzebecher J, Gläser D, Gabriel HH. Thrombin potential and thrombin generation after exhaustive exercise. Int J Sports Med. 2002;23:500–4.CrossRefPubMed
30.
go back to reference Huskens D, Roest M, Remijn JA, Konings J, Kremers RM, Bloemen S, Schurgers E, Selmeczi A, Kelchtermans H, van Meel R, Meex SJ, Kleinegris MC, De Groot PG, Urbanus RT, Ninivaggi M, de Laat B. Strenuous exercise induces a hyperreactive rebalanced haemostatic state that is more pronounced in men. Thromb Haemost. 2016;115:1109–19.CrossRefPubMed Huskens D, Roest M, Remijn JA, Konings J, Kremers RM, Bloemen S, Schurgers E, Selmeczi A, Kelchtermans H, van Meel R, Meex SJ, Kleinegris MC, De Groot PG, Urbanus RT, Ninivaggi M, de Laat B. Strenuous exercise induces a hyperreactive rebalanced haemostatic state that is more pronounced in men. Thromb Haemost. 2016;115:1109–19.CrossRefPubMed
31.
go back to reference Lamprecht M, Moussalli H, Ledinski G, Leschnik B, Schlagenhauf A, Koestenberger M, Polt G, Cvirn G. J Appl Physiol. 2013;115:57–63. 1985.CrossRefPubMed Lamprecht M, Moussalli H, Ledinski G, Leschnik B, Schlagenhauf A, Koestenberger M, Polt G, Cvirn G. J Appl Physiol. 2013;115:57–63. 1985.CrossRefPubMed
32.
go back to reference Bakovic D, Pivac N, Eterovic D, Palada I, Valic Z, Paukovic-Sekulic B, Dujic Z. Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoceptor blockade in hypertensive patients. Clin Exp Pharmacol Physiol. 2009;36:441–6.CrossRefPubMed Bakovic D, Pivac N, Eterovic D, Palada I, Valic Z, Paukovic-Sekulic B, Dujic Z. Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoceptor blockade in hypertensive patients. Clin Exp Pharmacol Physiol. 2009;36:441–6.CrossRefPubMed
33.
go back to reference Winther K, Willich SN. Beta 1-blockade and acute coronary ischemia. Possible role of platelets. Circulation. 1991;84:VI68–71.PubMed Winther K, Willich SN. Beta 1-blockade and acute coronary ischemia. Possible role of platelets. Circulation. 1991;84:VI68–71.PubMed
Metadata
Title
Pro-coagulant activity during exercise testing in patients with coronary artery disease
Authors
Joanna Cwikiel
Ingebjorg Seljeflot
Eivind Berge
Harald Arnesen
Kristian Wachtell
Hilde Ulsaker
Arnljot Flaa
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2017
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-016-0127-8

Other articles of this Issue 1/2017

Thrombosis Journal 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.